he efficacy of percutaneous coronary intervention (PCI) has been established for the treatment of patients with acute myocardial infarction (AMI), 1,2 and there is now increasing evidence from randomized trials that coronary stent placement yields significantly better results than balloon angioplasty. [3] [4] [5] [6] [7] [8] However, there is scant information available from routine clinical practice to determine the effects of stents on short-and long-term outcome. As in many randomized controlled studies, these trials included only a small proportion of selected patients, and the hospitals participating in the trials are particularly experienced and large-volume centers. In fact, previous subgroup analyses using the registry data from New York 9 and Germany, 10 and a retrospective analysis of a single institution's data, 11 could not observe a significant improvement in clinical outcomes in AMI patients receiving coronary stents. In contrast, a recent report from Veterans Affairs'
criteria were patients with AMI who presented within 6 h of symptom onset, or between 6 and 24 h if they had persistent symptoms with evidence of ongoing ischemia, including chest pain and ST-segment elevation in the infarct region. Patients in whom PCI was interrupted during the procedure (n=20) and those with an incomplete data set regarding the infarct-related artery (n=306) and in-hospital complications (n=3) were excluded. Further exclusions were patients who underwent other PCIs such as atherectomy or laser angioplasty in addition to balloon angioplasty or stent placement (n=12). Patients who had more than one lesion attempted were also excluded (n=14) because it was impossible to determine whether balloon angioplasty or stent placement was the only intervention attempted on all lesions. This approach led to the identification of 2,185 patients, 1,349 of whom underwent balloon angioplasty and 836 of whom underwent stent placement. For each patient, baseline demographic information, clinical factors, angiographic findings, procedural data, in-hospital and long-term outcomes were collected by the investigators in each institution.
Data Collection
The patients' demographic information, cardiovascular history, their risk factors (ie, hypercholesterolemia, smoking, hypertension, and diabetes mellitus) were recorded. Hypercholesterolemia was defined as total cholesterol ≥220 mg/dl; hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg; diabetes mellitus was defined as fasting blood sugar ≥140 mg/dl or blood sugar during a 75 g oral glucose tolerance test ≥200 mg/dl; renal failure was defined as serum creatinine ≥2.5 mg/dl. Single-vessel disease was defined as ≥51% stenosis in any of the major coronary arteries or their major branches, and multivessel disease was defined as ≥51% stenosis in either 2 or all 3 major epicardial coronary arteries. Further, the left ventricular ejection fraction (LVEF) was assessed by any method including left ventricular (LV) angiography, echocardiography, and radionuclide angiography, and categorized as (1) ≥50% and (2) <50% or unknown.
Outcome Follow-up data were obtained by reviewing the medical records and/or mail or telephone contact with the patients. 15 We assessed death and the use of revascularization procedures including repeat PCI and CABG during and after the 20 (0.12-0.33) 0.23 (0.12-0.45) p<0.0001 p<0.0001 hospitalization. Angiographic success was defined as successful dilation to ≤50% residual stenosis or Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow of the attempted lesions. Restenosis was defined as a final stenosis >50% at followup or a loss of at least 50% of the gain in luminal diameter achieved by PCI.
In-hospital follow-up data were collected for all patients. Long-term follow-up data were obtained in 1,914 of 2,030 discharged patients (94.3 %). The mean follow-up interval was approximately 1.9 years in both groups (697±174 days for the angioplasty group and 699±179 days for the stent group; p=0.808).
Statistical Analysis
Patient characteristics and outcomes were compared between the angioplasty and stent groups; chi-square statistic was used for categorical variables and unpaired t test for continuous variables. As for in-hospital outcomes, odds ratios (OR) for patients treated with balloon angioplasty as compared with stenting were calculated by logistic regression analysis. Long-term outcomes in the 2 groups were examined by Kaplan-Meier curves, and Cox's proportionalhazards models were used to calculate relative risk. Adjustment was made for variables potentially associated with treatment selection including age, gender, previous MI, hypercholesterolemia, smoking, hypertension, diabetes mellitus, renal failure, cerebrovascular disease, prior PCI, prior CABG, attempted lesion, number of diseased vessels, and LVEF. Both short-and long-term outcomes were also compared for angioplasty vs stenting within subgroups classified by the baseline characteristics: number of diseased vessels, proximal left anterior descending (LAD) disease, diabetes mellitus, and normal/abnormal LVEF. Statistical analyses were performed by using the SAS (version 8.1), and a two-sided p value less than 0.05 was regarded as statistically significant.
Results
Patient characteristics including demographic data, medical history, risk factors, and angiographic data are shown in Table 1 . As noted, patients treated by balloon angioplasty were less often males and were more likely to have had a left circumflex coronary artery lesion than patients treated by stents. There were no significant differences in other variables between the 2 groups of patients.
Even though the rate of angiographic success was higher in the stent group (89.7 vs 97.7 %, p<0.0001), the in-hospital mortality rate was comparable (7.6 vs 6.3%) between the balloon angioplasty and stent groups ( Table 2 ). Even after adjustment for all potentially confounding factors, the risk of in-hospital mortality was similar (OR 0.75). The adjusted rates of need for repeat PCI or CABG during the hospitalization were also comparable between the 2 groups. Fig 1 shows the adjusted OR for in-hospital mortality for 8 subgroups of patients: single and multivessel disease, proximal LAD and non-LAD disease, diabetes and nondiabetes, and normal and abnormal or missing LV function data. Inhospital mortality was comparable in all subgroups that were examined. Even though the in-hospital mortality in the stent group tended to be lower in the subgroup of proximal LAD disease (10.2 vs 7.0 %), this difference did not reach statistical significant (p=0.053).
Despite the benefits of stents in reducing restenosis (44.5 vs 34.2 %, p<0.0001), they were not associated with a statistically significant reduction in long-term outcomes including all cause mortality, cardiac mortality, or the need for revascularization procedures (Table 3 ). All results were essentially unchanged even after adjustment for all potentially confounding variables. Fig 2 represents Odds ratios for in-hospital mortality with confidence intervals (CI) for balloon angioplasty versus stents were obtained from logistic regression analysis models comparing balloon angioplasty and stents with adjustment for all variables for the entire group and within each of the specified subgroups. LAD, left anterior descending coronary artery. LV, left ventricle.
rates were similar. In addition to mortality rates, the requirement for repeat PCI or CABG was also similar (Fig 3) . Fig 4 shows the adjusted mortality relative risks for longterm mortality for balloon angioplasty and stent placement for 8 subgroups of patients as shown in Fig 1. Again, adjusted post-discharge mortality rates were comparable in all subgroups analyzed.
Discussion
The present study demonstrated that stent placement did not significantly reduce the risk of in-hospital mortality and the need for subsequent revascularization compared with balloon angioplasty in patients with AMI despite a significantly higher angiographic success. Further, stents reduced the incidence of restenosis of the infarcted coronary artery, but did not affect the long-term mortality and the need for revascularization procedures including repeat PCI or CABG after discharge.
Previous randomized clinical trials comparing balloon angioplasty with stent placement in the treatment of patients with AMI have demonstrated improved short-and long-term outcomes in the stent-treated patients. [3] [4] [5] [6] [7] [8] In contrast, the present study analyzing broad-based registry patients with AMI could not demonstrate any benefits in coronary stenting compared with balloon angioplasty.
There are several explanations for the lack of a beneficial relationship between stents and clinical outcomes. First, this is not a randomized clinical trial. Consequently, the choice of treatment was influenced by the attending physician's decision. It is possible that patients receiving stents were at higher risk of cardiac events, therefore making a truly beneficial effect of stenting. In fact, there was a small, although statistically insignificant, excess of patients with left main disease (1.0 vs 1.4 %, p=0.31) in the stent group (Table 1 ). In addition, more patients with a left circumflex lesion were treated with balloon angioplasty (13.9 vs 8.9 %, p<0.01) and this group of patients might have had a reasonably good prognosis. 11 However, the 2 patient groups were quite similar with respect to preprocedural risk factors. Furthermore, we attempted to minimize the treatment selection bias by adjusting the differences among patients in the prevalence of potentially confounding demographic, clinical, and angiographic variables. Therefore, uncontrolled confounding is unlikely to explain the results. Despite this, it cannot be excluded that patients undergoing stent placements might have had clinical signs of severity that escaped the usual clinical description taken into account in the present study. Second, stents used as bailout therapy for abrupt closure (not discernible from the data set in this study) might increase the risk of adverse outcomes in the stent group. 16 Third, the design of the present study could result in a failure to detect a reduction in risk from stents because of chance. However, the consistency of the lack of benefit in the different subgroups suggests that these findings were not from chance. Fourth, an even higher risk for in-hospital adverse outcomes with coronary stenting compared with balloon angioplasty has been shown, 17 and might be related to slower antegrade flow after stenting, 18 which is at least partly attributable to thrombus formation at the site of stent implantation followed by distal embolization. 19 Therefore, stenting might have reduced epicardial flow, which would have adversely affected the in-hospital outcomes in the present study. Whatever the reason, the present findings are consistent with those obtained from the New York 9 and German registries, 10 which both found that there was not a short-or long-term outcome benefit for stent placement in patients with AMI. The similarities between those 2 registries and ours are striking, and are also supported by a recent retrospective analysis of patients with AMI treated with PCI. 11 Given the larger sample sizes, registry data can be an important supplement to randomized clinical trial data.
The present study demonstrated that stents reduced the incidence of restenosis, but not the need for revascularization (Table 3) . Even though the angiographic findings, such as reference coronary artery diameter and minimal luminal diameter, were not available for the present study, there are several potential explanations for this finding. First, more of the patients treated with balloon angioplasty might not have undergone revascularization despite the occurrence of angiographic restenosis. Second, the diameter of stents might have been too small and the inflation pressure might have been too low, which would increase the rate of restenosis in the stent-treated patients.
In considering the findings between randomized trials and observational studies, one has to keep in mind that the patient population in randomized multicenter clinical trials may be a selected group of patients with a low risk profile compared with the large-scale observational studies from a more diverse range of hospitals and patients. Recently, it has been postulated that the same selection bias contributes to the differences in the results between randomized controlled studies 20, 21 and nonrandomized, observational studies comparing thrombolysis with primary angioplasty. 22 Registries can document the relationship between therapeutic modalities used in the real world and clinical outcomes, despite their methodological biases; in particular the comparability of different groups of patients receiving different treatments. Therefore, further evaluation is needed before we can definitively recommend routine stent placement as the standard care for patients with AMI.
Study Limitations
First, important angiographic variables, such as target lesion morphology, as well as clinical variables, such as cardiogenic shock, heart failure and antecedent thrombolytic therapy, were not included in the present study. In addition, the lack of information on medications, such as -blockers, angiotensin-converting enzyme inhibitors and statins, is also a potential limitation. These variables should be included in the future registry. Second, the present study was performed before platelet glycoprotein IIb/IIIa inhibitors were available in Japan. Previous studies reported more cardiac events with stent placement and argued that stenting might actually increase risk in the absence of glycoprotein IIb/IIIa inhibitors. 23, 24 The introduction of glycoptrotein IIb/IIIa receptor inhibitors into PCI practice may improve immediate clinical outcome as well as reduce the requirement for repeat PCI. However, the limitation of the inclusion of patients in the era before glycoprotein IIb/IIIa inhibitors does have the advantage of permitting the present study to examine the effects of stenting independent of the effects of these drugs. Third, the practice of interventional cardiology continues to change with improvements in stent design, increasing experience of cardiologists with the techniques, and more appropriate use of adjunct pharmacotherapy. Therefore, continual assessment of progress in the evolution of PCI is essential.
Conclusions
Stent placement in the present broad-based cohort of patients with AMI did not show superior short-or long-term clinical outcomes compared with balloon angioplasty.
